The GLP-1 compounding story: how it got here
Published October 26, 2026. About US policy and data. News summary, cited below.
Quick take: compounding was meant for individual patient needs and shortages. In 2026 the FDA moved to pull it back for mass marketed GLP-1 copies.
The timeline
| When | What |
|---|---|
| Feb 6, 2026 | FDA says it will restrict active ingredients used in mass marketed compounded semaglutide and tirzepatide, and act on misleading "generic" or "equivalent" claims |
| End of May 2026 | 990 adverse event reports on compounded semaglutide and over 730 on compounded tirzepatide |
| Sep 4, 2026 | FDA numbers reported publicly, with a note that they may undercount |
What the FDA said compounding is for
Limited to a patient specific medical need or a drug shortage, not mass production, per the report. Some analysts see this approach as a possible template for regulating wellness peptides.
Why a report is not proof
An adverse event report does not prove the drug caused the problem. Read more in what the numbers mean.
What to ask
- Why was a compounded version chosen?
- Which pharmacy made it?
- Is the peptide approved for human use?
Ready to order?
Paste it in the Promo code box in the order summary at checkout, then press Apply. Confirm the discount line before you pay.
Common questions
What is compounding?
A pharmacy preparing a customized medication for an individual patient.
What did the FDA do in February 2026?
It said it would restrict ingredients used in mass marketed compounded GLP-1 drugs.
Do reports prove harm?
No. The FDA says a report does not prove causation.
Sources
- AJMC: 5 things to know about the FDA's peptide reversal (Aug 21, 2026)
- WBAY: FDA tracking hundreds of reports tied to compounded weight-loss drugs and unapproved peptides (Sep 4, 2026)
Summarised in my own words. Read the originals for the full detail.